China's Antibody Sales Market Reach $3.16 Billion

---

Researched by Industrial Info Resources (Sugar Land, Texas)--According to MedChina, the sales market for antibody drugs in China in 2021 reached US$3.16 billion, and the global sales market reached US$180 billion.

Industrial Info is tracking 32 active antibody projects in China, worth US$2.1 billion, most of which are related to monoclonal antibodies (mAbs). Subscribers to Industrial Info's Global Market Intelligence (GMI) Pharmaceutical & Biotech Project Database can click here for a full list of detailed project reports.

Sinopharm Group features the largest expenditure: a $246 billion grassroot antibody plant in Shanghai. The project entails building two 24,000-liter stock solution production lines, two antibody-manufacturing workshops, refrigerated storage warehouses and office buildings.

Industrial Info Resources (IIR), with global headquarters in Sugar Land, Texas, six offices in North America and 12 international offices, is the leading provider of global market intelligence specializing in the industrial process, heavy manufacturing and energy markets. Industrial Info's quality-assurance philosophy, the Living Forward Reporting Principle, provides up-to-the-minute intelligence on what's happening now, while constantly keeping track of future opportunities. Follow IIR on: Facebook - Twitter - LinkedIn.